180 related articles for article (PubMed ID: 21273389)
1. Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?
Frauenfelder T; Tutic M; Weder W; Götti RP; Stahel RA; Seifert B; Opitz I
Eur Respir J; 2011 Jul; 38(1):162-8. PubMed ID: 21273389
[TBL] [Abstract][Full Text] [Related]
2. Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT.
Plathow C; Klopp M; Thieke C; Herth F; Thomas A; Schmaehl A; Zuna I; Kauczor HU
Eur Radiol; 2008 Aug; 18(8):1635-43. PubMed ID: 18369634
[TBL] [Abstract][Full Text] [Related]
3. Three-dimensional evaluation of chemotherapy response in malignant pleural mesothelioma.
Ak G; Metintas M; Metintas S; Yildirim H; Ozkan R; Ozden H
Eur J Radiol; 2010 Apr; 74(1):130-5. PubMed ID: 19268516
[TBL] [Abstract][Full Text] [Related]
4. Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.
Schaefer NG; Veit-Haibach P; Soyka JD; Steinert HC; Stahel RA
Eur J Radiol; 2012 Jan; 81(1):e19-25. PubMed ID: 21129871
[TBL] [Abstract][Full Text] [Related]
5. Volumetric evaluation of therapy response in patients with lung metastases. Preliminary results with a computer system (CAD) and comparison with unidimensional measurements.
Fraioli F; Bertoletti L; Napoli A; Calabrese FA; Masciangelo R; Cortesi E; Catalano C; Passariello R
Radiol Med; 2006 Apr; 111(3):365-75. PubMed ID: 16683084
[TBL] [Abstract][Full Text] [Related]
6. Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer-aided volumetric measurement on computed tomography scans.
Liu F; Zhao B; Krug LM; Ishill NM; Lim RC; Guo P; Gorski M; Flores R; Moskowitz CS; Rusch VW; Schwartz LH
J Thorac Oncol; 2010 Jun; 5(6):879-84. PubMed ID: 20421814
[TBL] [Abstract][Full Text] [Related]
7. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose.
Ceresoli GL; Chiti A; Zucali PA; Rodari M; Lutman RF; Salamina S; Incarbone M; Alloisio M; Santoro A
J Clin Oncol; 2006 Oct; 24(28):4587-93. PubMed ID: 17008700
[TBL] [Abstract][Full Text] [Related]
8. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
Byrne MJ; Nowak AK
Ann Oncol; 2004 Feb; 15(2):257-60. PubMed ID: 14760119
[TBL] [Abstract][Full Text] [Related]
9. CT, RECIST, and malignant pleural mesothelioma.
Nowak AK
Lung Cancer; 2005 Jul; 49 Suppl 1():S37-40. PubMed ID: 15950799
[TBL] [Abstract][Full Text] [Related]
10. Correlation of patient survival with clinical tumor measurements in malignant pleural mesothelioma.
Li F; Ahmad M; Qayyum F; Straus CM; MacMahon H; Kindler H; Armato SG
Eur Radiol; 2019 Jun; 29(6):2981-2988. PubMed ID: 30617480
[TBL] [Abstract][Full Text] [Related]
11. Assessment of tumor response in malignant pleural mesothelioma.
Ceresoli GL; Chiti A; Zucali PA; Cappuzzo F; De Vincenzo F; Cavina R; Rodari M; Poretti D; Lutman FR; Santoro A
Cancer Treat Rev; 2007 Oct; 33(6):533-41. PubMed ID: 17764849
[TBL] [Abstract][Full Text] [Related]
12. Volume-based parameter of 18)F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications.
Lee HY; Hyun SH; Lee KS; Kim BT; Kim J; Shim YM; Ahn MJ; Kim TS; Yi CA; Chung MJ
Ann Surg Oncol; 2010 Oct; 17(10):2787-94. PubMed ID: 20461469
[TBL] [Abstract][Full Text] [Related]
13. Staging and response to therapy of malignant pleural mesothelioma.
Heelan R
Lung Cancer; 2004 Aug; 45 Suppl 1():S59-61. PubMed ID: 15261435
[TBL] [Abstract][Full Text] [Related]
14. What is the best way to diagnose and stage malignant pleural mesothelioma?
Zahid I; Sharif S; Routledge T; Scarci M
Interact Cardiovasc Thorac Surg; 2011 Feb; 12(2):254-9. PubMed ID: 21044972
[TBL] [Abstract][Full Text] [Related]
15. Measurement of response of pulmonal tumors in 64-slice MDCT.
Sohns C; Mangelsdorf J; Sossalla S; Konietschke F; Obenauer S
Acta Radiol; 2010 Jun; 51(5):512-21. PubMed ID: 20540683
[TBL] [Abstract][Full Text] [Related]
16. Fully automated volumetric measurement of malignant pleural mesothelioma by deep learning AI: validation and comparison with modified RECIST response criteria.
Kidd AC; Anderson O; Cowell GW; Weir AJ; Voisey JP; Evison M; Tsim S; Goatman KA; Blyth KG
Thorax; 2022 Dec; 77(12):1251-1259. PubMed ID: 35110367
[TBL] [Abstract][Full Text] [Related]
17. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response.
Erasmus JJ; Gladish GW; Broemeling L; Sabloff BS; Truong MT; Herbst RS; Munden RF
J Clin Oncol; 2003 Jul; 21(13):2574-82. PubMed ID: 12829678
[TBL] [Abstract][Full Text] [Related]
18. Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study.
Gudmundsson E; Labby Z; Straus CM; Sensakovic WF; Li F; Rose B; Cunliffe A; Kindler HL; Armato SG
Eur Radiol; 2019 Feb; 29(2):682-688. PubMed ID: 29967955
[TBL] [Abstract][Full Text] [Related]
19. [Current insights in malignant pleural mesothelioma].
Bard M; Debrosse D; Caliandro R; Girard P; Grunenwald D; Ruffié P
Bull Cancer; 2002 Jan; 89(1):67-74. PubMed ID: 11847028
[TBL] [Abstract][Full Text] [Related]
20. Computer-aided volumetric assessment of malignant pleural mesothelioma on CT using a random walk-based method.
Chen M; Helm E; Joshi N; Gleeson F; Brady M
Int J Comput Assist Radiol Surg; 2017 Apr; 12(4):529-538. PubMed ID: 28028655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
